I make a donation

ADEN

Genetics-guided antiplatelet monotherapy Vs standard early de-escalation with ticagrelor or prasugrel at 1 month after ACS in patients at risk of bleeding.

En cours

Colloquium "Endocardite infectieuse" (jeudi 07 novembre 2024)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

Pod'casts Interview d'experts

P&R Agenda
Au programme prochainement...

Parole & Réaction vous invite à découvrir les Pod'P&R, les pod'casts d'infos médicales !

objectif

Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

date de réalisation

2024

nombre de patients

2468

nombre de centres participants

Multicentric trial (26 french sites)

type de financement

Public (APHP)

Référence

NCT05577988

Autres études

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI

ARGONAUT

En cours

Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device related intra cardiac thrombus : a randomized Assessment Under direct oral antic...

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....